Evidence map›Paper›PMID 39819811›Full record

ArticleJMIR cancer2025

Developing and Assessing a Scalable Digital Health Tool for Pretest Genetic Education in Patients With Early-Onset Colorectal Cancer: Mixed Methods Design.

Jessica N Rivera Rivera, Moran Snir, Emilie Simmons, Tara Schmidlen, Misha Sholeh, Melinda Leigh Maconi, Carley Geiss, Hayden Fulton, Laura Barton, Brian D Gonzalez and 2 more

Abstract read
In one paragraph

Article in JMIR cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jessica N Rivera RiveraHealthcare Delivery Research Network, MedStar Health Research Institute, Washington, DC, United States.ORCID 0000-0002-6675-0037
Moran SnirNest Genomics, New York, NY, United States.ORCID 0009-0006-3919-9506
Emilie SimmonsNest Genomics, New York, NY, United States.ORCID 0009-0004-1646-8801
Tara SchmidlenNest Genomics, New York, NY, United States.ORCID 0000-0002-9749-112X
Misha SholehNon-Therapeutic Research Office, Moffitt Cancer Center, Tampa, FL, United States.ORCID 0009-0006-4189-4380
Melinda Leigh MaconiParticipant Research, Interventions, and Measurement Core, Moffitt Cancer Center, Tampa, FL, United States.ORCID 0000-0002-4357-2514
Carley GeissParticipant Research, Interventions, and Measurement Core, Moffitt Cancer Center, Tampa, FL, United States.ORCID 0000-0003-3800-1132
Hayden FultonParticipant Research, Interventions, and Measurement Core, Moffitt Cancer Center, Tampa, FL, United States.ORCID 0000-0003-0486-6277
Laura BartonDepartment of Pathology, Moffitt Cancer Center, Tampa, FL, United States.ORCID 0000-0002-3750-5745
Brian D GonzalezResearch Diversity and Workforce Development, Moffitt Cancer Center, Tampa, FL, United States.ORCID 0000-0001-5108-5735
Jennifer PermuthDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.ORCID 0000-0002-4726-9264
Susan VadaparampilDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States.ORCID 0000-0002-1052-6917

Funding

Behavioral Oncology Education & Career DevelopmentT32CA090314 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI Vani N Simmons, SUSAN T VADAPARAMPIL · 2019 to 2026
$2.9M
NCI NIH HHS T32 CA090314
6 · The paper itself

Abstract

backgroundNational guidelines recommend germline genetic testing (GT) for all patients with early-onset colorectal cancer. With recent advances in targeted therapies and GT, these guidelines are expected to expand to include broader groups of patients with colorectal cancer. However, there is a shortage of genetic professionals to provide the necessary education and support for informed consent. As such, there is a pressing need to identify alternative approaches to facilitate and expedite access to GT.

objectiveThis study describes the development of a pretest education intervention, Nest-CRC, to facilitate the uptake of germline GT among patients with early-onset colorectal cancer. Patients with early-onset colorectal cancer and health care providers reviewed Nest-CRC, and their reactions and recommendations were captured using a nested mixed methods approach.

methodsUsing the learner verification approach, we conducted 2 sequential phases of surveys and interviews with English- and Spanish-speaking patients with early-onset colorectal cancer and health care providers. The surveys assessed participants' experiences with genetic services and provided immediate feedback on the Nest-CRC genetic education modules. Semistructured interviews evaluated participants' perceptions of self-efficacy, attraction, comprehension, cultural acceptability, and usability of Nest-CRC. Survey data were analyzed using descriptive statistics (mean, median, and proportions), while interview data were analyzed through line-by-line coding of the transcribed interviews. After each phase, Nest-CRC was refined based on participants' recommendations.

resultsA total of 52 participants, including 39 patients with early-onset colorectal cancer and 13 providers, participated in the study. Of these, 19 patients and 6 providers participated in phase 1 (N=25), and 20 patients and 7 providers participated in phase 2 (N=27). Most participants (phase 1: 23/25, 92%, to 25/25, 100%; phase 2: 24/27, 89%, to 27/27, 100%) agreed that each of the 5 education modules was easy to understand and helpful; 13 patients reported no history of GT, with 11 (85%) expressing interest in GT and 2 (15%) remaining unsure after completing Nest-CRC. Participants reported that Nest-CRC provided sufficient information to help them decide about GT. The tool was deemed acceptable by individuals from diverse backgrounds, and participants found it visually attractive, easy to comprehend, and user-friendly.

conclusionsThe findings revealed that Nest-CRC is a promising strategy for facilitating pretest education and promoting GT. Nest-CRC has been refined based on participant recommendations and will be re-evaluated.

Indexed as

Colorectal NeoplasmsGenetic TestingPatient Education as TopicAdultAge of OnsetDigital HealthFemaleGerm-Line MutationHealth PersonnelHumansMaleMiddle AgedSurveys and Questionnairesdigital healthearly-onset colorectal cancergenetic counselinggenetic educationgenetic testing

Identifiers

PMID39819811
PMCPMC11786131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.